Insilico Medicine announced that its Founder and CEO, Alex Zhavoronkov, PhD, has been named to the inaugural SCW75 list by Scientific Computing World, honoring the world's most influential leaders advancing scientific computing. Zhavoronkov was recognized for pioneering the application of AI, high-performance computing, and large-scale data analysis to drug discovery, longevity research, and biotechnology innovation. Through Insilico's Pharma.AI platform, the company has advanced 30 developmental candidates, including 13 clinical-stage programs, while expanding AI-driven molecular design into sustainability applications such as carbon capture and clean energy technologies. The recognition underscores the increasing impact of scientific computing on medicine, human health, and industrial innovation.

Breast cancer can remain dormant in the bone marrow for decades before reactivating, resulting in cancer relapse. A study published in Bone Research unveils the critical role of Notch2 signaling pathway in promoting this dormant state. The study explains how dormant cancer cells mimic healthy stem cells and activate stress pathways to survive in the bone marrow—paving the way for innovative targeted therapies against dormant cancer cells.

A pilot study has developed a new sensory evaluation method that links the chemical structures of polyphenols with their distinct taste properties. Using trained human panelists, researchers showed that different polyphenols produce unique sensory effects, including bitterness, acidity, and astringency. The findings may help improve functional food design and food processing technologies while advancing understanding of how taste-related sensory pathways contribute to digestion, metabolism, and health-related responses.